OIE Reference Laboratory Reports
Activities in 2011
Name of disease (or topic) for
which you are a designated OIE
Reference Laboratory:
Address of laboratory:
Central Veterinary Institute of Wageningen UR
P.O. Box 65
8200AB Lelystad
THE NETHERLANDS
Tel.:
+31 320 238800
Fax:
+31 320 238668
e-mail address:
website:
Name (including Title and
Position) of Head of Laboratory
(Responsible Official):
Name(including Title and
Position) of OIE Reference
Expert:
Name (including Title and
Position) of writer of this report
(if different from above):
Annual reports of OIE Reference Centres, 2011
Aujeszky’s disease
(Pseudorabies)
andre.bianchi@wur.nl
www.cvi.wur.nl
Willie Loeffen, DVM, PhD
Project leader CSF, ASF
and Aujeszky’s disease
Andre Bianchi, PhD
Director of CVI
Willie Loeffen
1
Aujeszky’s disease
Part I: Summary of general activities related to the disease
1.
Test(s) in use/or available for the specified disease/topic at your laboratory
Test
For
Specificity
Total
ELISA
Antibody
gE
36
ELISA
Antibody
gE-confirmation (other domains)
48
ELISA
Antibody
gB
1125
VN
Antibody
Whole virus
10
SK6 cell culture
Virus isolation
Whole virus
0
PCR
Genome detection
gE
42
PCR
Genome detection
gB
23
Numbers given are for diagnostic tests on samples received from third parties (mainly surveillance and
suspicions). Additional tests were carried out on animal experiments, in the framework of ring trials and
validation/accreditation purposes of the tests.
2.
Production and distribution of diagnostic reagents
All batches of commercially available gE and gB-ELISA kits are being checked before they are allowed to be used
by the regional labs in the Netherlands (currently 2 other labs) for large scale surveillance of Aujeszky’s disease.
The performance of these regional labs is under constant monitoring by providing 2 internal control sera, to be
used in every test, and a proficiency test (33 sera) to be carried out twice per year. In 2011 a request for reference
materials was received from the Ukrainian reference lab. Virus and sera were sent to the lab.
Part II: Activities specifically related to the mandate
of OIE Reference Laboratories
3.
International harmonisation and standardisation of methods for diagnostic testing or the
production and testing of vaccines
a)
Establishment and maintenance of a network with other OIE Reference Laboratories
designated for the same pathogen or disease and organisation of regular inter-laboratory
proficiency testing to ensure comparability of results
Participation in the first International Workshop for Aujeszky's disease, Ploufragan, France, 23-24 June 2011,
organised by the French OIE laboratory for Aujeszky;s disease.
b)
Organisation of inter-laboratory proficiency testing with laboratories other than OIE
Reference Laboratories for the same pathogens and diseases to ensure equivalence of
results
In 2011 we participated in three ring trials (serology: gE-ELISA, gB-ELISA, VNT) organized by the VLA
(UK). No international ringtrials were organised by our lab.
2
Annual reports of OIE Reference Centres, 2011
Aujeszky’s disease
4.
Preparation and supply of international reference standards for diagnostic tests or vaccines
We hold in stock a set of reference sera for use in the gE and gB ELISA, as well as a batch of standard virus to be
used in a VNT. Furthermore, we hold a set of monoclonal antibodies against a range of epitopes of different PRV
glycoproteins.
5.
Research and development of new procedures for diagnosis and control
None.
6.
Collection, analysis and dissemination of epizootiological data relevant to international disease
control
No PR viruses were isolated from the Netherlands. Based on serological surveillance no suspicions were raised in
2011.
7.
Maintenance of a system of quality assurance, biosafety and biosecurity relevant to the
pathogen and the disease concerned
Main diagnostic tests (PCR and ELISA’s) are accredited according to ISO 17025. Other tests (VI, VNT) and
laboratory management are accredited according to ISO 9001. Currently all work with Aujeszky’s disease virus
takes place within BSL3 facilities.
8.
Provision of consultant expertise to OIE or to OIE Member Countries
None.
9.
Provision of scientific and technical training to personnel from other OIE Member Countries
None.
10. Provision of diagnostic testing facilities to other OIE Member Countries
We carry out confirmation diagnostics for the Belgian reference laboratory. Samples for confirmation/exclusion of
an Aujeszky’s disease outbreak were received from Finland (oropharyngeal swabs and sera). All samples tested
negative in the PCR and the ELISA (both gE and gB).
11. Organisation of international scientific meetings on behalf of OIE or other international bodies
None.
12. Participation in international scientific collaborative studies
None.
13. Publication and dissemination of information relevant to the work of OIE (including list of
scientific publications, internet publishing activities, presentations at international conferences)

Presentations at international conferences and meetings
Loeffen, W. Aujeszky’s Disease - Recognition of regional laboratories. International Workshop for Aujeszky's
disease, Ploufragan, France, 23-24 June 2011.
_______________
Annual reports of OIE Reference Centres, 2011
3